NHS National Generic Pharmaceuticals Wave 13
This is a large award for Medical Equipment & Pharmaceuticals — above three-quarters of comparable contracts. Based on 9,456 valued Medical Equipment & Pharmaceuticals tenders in our corpus.
Invitation to offer for NHS National Generic Pharmaceuticals Wave 13 Offer reference number: CM/PHG/17/5532 Period of framework agreement: The total maximum duration of the framework agreement to be no more than 28 months, with an option or options to extend (at the Authority's sole discretion) for a period or periods up to a total of 48 months.
Potential periods of call-offs under the framework agreement: Transition (Everolimus) CESW: 1 March 2022 - 30 September 2023 (19 months) LSNE: 1 March 2022 - 31 January 2023 (11 months) NWLN: 1 March 2022 - 31 January 2023 (11 months) Oral Products plus non-parenterals All Regions: 1 March 2022 - 31 May 2024 (27 months) Hospital Only Products CESW: 1 February 2022 - 30 September 2023 (20 months) LSNE: 1 February 2022 - 31 May 2024 (28 months) NWLN: 1 February 2022 - 31 January 2023 (12 months)
Make the case to bid
Reveal who to approach at ATAMIS LTD, and generate a go-to-market strategy from their news, accounts and people.
- OCID
- f872d76f-37e6-4b7e-b25e-c952ac8a42eb
- Stage
- contract · Contract
- Source
- Contracts Finder
- Buyer ref
- CF-0584600D0O000000rwimUAA2
Contains public sector information licensed under the Open Government Licence v3.0. Source data © Crown copyright.
Who wins this kind of work
The suppliers and buyers around this opportunity — drawn from official award data. Drag to orbit; click a node to explore.
Top suppliers & buyers in Medical Equipment & Pharmaceuticals
Assembling the market network…
ATAMIS LTD’s tender network
Assembling the network…